adhd - Page 1 | CARLAT PUBLISHING

Alpha-2 Agonists Review: Clonidine (Kapvay) and Guanfacine (Intuniv), Non-Stimulant ADHD Medications

October 6, 2024

In this video, we explore the use of alpha-2 agonists in the treatment of ADHD, specifically focusing on guanfacine ER (Intuniv) and clonidine ER (Kapvay). These non-stimulant ADHD medications have become viable options for patients who may not tolerate stimulants or have comorbid conditions that make stimulant medications less effective or problematic.

CARLAT WEBINAR

How to Select a Stimulant Formulation

December 6, 2022

Chris Aiken, MD

0.50 CME Credits. Which isomer mix should you choose, and which release mechanism is the best fit for your patient?

Interpreting Assessment Discrepancies from Multiple Sources

October 17, 2022

Joshua Feder, MD and Mara Goverman

In this episode, we will discuss why assessment discrepancies arise, how we can manage them, and what these discrepancies tell us about a patient’s symptoms and response to treatment.

Amphetamine vs Methylphenidate

October 5, 2022

Chris Aiken, MD

0.50 CME Credits. Clinicians should understand how amphetamine and methylphenidate differ in respect to their: risks of psychosis, mania, and substance use, neurotoxic and neuroprotective properties, efficacy and tolerability, and use across the lifespan.

CLINICAL UPDATE

A Diet for ADHD

September 25, 2022

Chris Aiken, MD and Uma Naidoo, MD

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report.

Uma Naidoo, MD. Director of Nutritional and Metabolic Psychiatry, Massachusetts General Hospital (MGH); Director of Nutritional & Lifestyle Psychiatry, MGH Academy; Author, This Is Your Brain on Food (Little, Brown Spark; 2020).

The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

After years of suggestive studies, the first randomized controlled to test a practical approach to diet in ADHD is out. Find out which foods to eat, and which to avoid.

Expert Q&A

Advances in College Mental Health

September 2, 2022

Michelle Riba MD, Garrett Rossi, MD., and Chris Aiken, MD

Michelle B. Riba, MD, MS

Professor, Department of Psychiatry; Co-Director, Workplace Mental Health Solutions, Eisenberg Family Depression Center; Director, PsychOncology Program, University of Michigan Rogel Cancer Center. Editor, College Psychiatry: Strategies to Improve Access to Mental Health (co-editor: Meera Menon, MD).

Interview by Garrett Rossi, MD. Inpatient/consult attending psychiatrist, AtlantiCare Regional Medical Center, Pomona, NJ.

Dr. Riba, expert of this educational activity, has disclosed that she receives book royalties from Springer, Wiley, and APA Publishing. Dr. Aiken has reviewed this educational activity and has determined that there is no commercial bias as a result of this financial relationship. Dr. Rossi has no relevant financial relationship(s) with ineligible companies to disclose.

College life is not what it used to be, and Dr. Riba shares ways to improve psychiatric care for students facing COVID lockdowns, financial strain, and the contagion of campus suicide.

ADHD: Beyond Stimulants

August 15, 2022

Chris Aiken, MD and Kellie Newsome, PMHNP

Richard Brown discusses symptoms that often get in the way of full recovery in ADHD, including dyslexia, and problems with working memory, processing speed, and executive function.

EXPERT Q&A

Complementary Therapy in ADHD

August 1, 2022

Richard P. Brown, MD

Richard P. Brown, MD

Clinical Professor of Psychiatry at Columbia University. Author of over 80 articles and books on clinical psychiatry, including Non-Drug Treatments for ADHD (WW Norton, 2012).

Dr Brown, expert for this educational activity, has no relevant financial relationship(s) with ineligible companies to disclose.

Richard Brown advances our understanding of CAM treatments for ADHD and updates us on what works and what doesn’t in clinical practice.

How Effective is Atomoxetine in Children and Adolescents

June 27, 2022

Joshua Feder, MD and Mara Goverman

With the recent approval of another non-stimulant ADHD medication (viloxazine, brand name Qelbree), this is a good time to revisit atomoxetine.

Practical Issues with Prescribing ADHD Meds

March 24, 2022

Anne Buchanan, DO

Anne Buchanan, DO

Child & Adolescent Psychiatrist with New York City Health and Hospitals, Bellevue, and Maimonides Medical Center in New York, NY.

Dr. Buchanan has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

There are so many newer medications for ADHD. Should we be trying them out sooner or waiting until our patients have failed several trials of older preparations? We talk with Dr. Anne Buchanan who guides us through this process, and we give you a handy chart of the newer medications as well.